Printer Friendly

Merck Serono signs contract with Sutro Biopharma.

M2 EQUITYBITES-September 19, 2014-Merck Serono signs contract with Sutro Biopharma


Germany-based Merck Serono has signed a collaboration and license agreement with United States-based Sutro Biopharma, it was reported yesterday.

The contract has been signed to develop antibody drug conjugates. Both firms will jointly discover and develop multiple antibody drug conjugates, antibodies linked to cytotoxic drugs for more targeted delivery, using Sutro's cell-free protein synthesis platforms Xpress CF and Xpress CF+.

Under the contract, Sutro will be responsible for delivering antibody drug conjugates for Phase I clinical trials, while Merck Serono retains responsibility for clinical development and commercialisation of any resulting products. Merck will make an upfront payment to Sutro and will fund certain R&D activities, while its partner stands to receive payments on completion of certain research, development and regulatory milestones of about EUR230m and royalties on product sales in return.

((Comments on this story may be sent to

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Sep 19, 2014
Previous Article:ADM Tronics elects Dr Gianluca DeNovi to advisory board.
Next Article:Scottish No vote makes RBS contingency plans void.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |